Dynasty Wealth Management LLC Raises Holdings in Zoetis Inc. (NYSE:ZTS)

Dynasty Wealth Management LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 20.3% during the fourth quarter, Holdings Channel reports. The institutional investor owned 23,076 shares of the company’s stock after purchasing an additional 3,887 shares during the quarter. Dynasty Wealth Management LLC’s holdings in Zoetis were worth $3,760,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of ZTS. Atlantic Edge Private Wealth Management LLC boosted its position in shares of Zoetis by 482.8% during the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock worth $28,000 after purchasing an additional 140 shares in the last quarter. Darwin Wealth Management LLC acquired a new position in Zoetis during the third quarter worth about $31,000. First Personal Financial Services purchased a new position in Zoetis in the third quarter valued at about $33,000. Capital Performance Advisors LLP acquired a new stake in shares of Zoetis during the 3rd quarter valued at approximately $33,000. Finally, Dunhill Financial LLC grew its holdings in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of the company’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $171.18, for a total value of $55,804.68. Following the completion of the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Zoetis Price Performance

ZTS opened at $164.95 on Friday. The company has a 50 day moving average of $166.25 and a two-hundred day moving average of $177.49. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. The company has a market cap of $73.86 billion, a P/E ratio of 30.16, a P/E/G ratio of 2.78 and a beta of 0.90.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.32 billion for the quarter, compared to analysts’ expectations of $2.30 billion. On average, analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.21%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio (DPR) is 36.56%.

Wall Street Analysts Forecast Growth

ZTS has been the subject of several research reports. Piper Sandler lifted their price objective on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday. UBS Group began coverage on shares of Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price objective on the stock. Morgan Stanley reduced their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Stifel Nicolaus dropped their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $215.90.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.